News from our community and beyond
Every month we provide our subscribers with some of the latest news about our projects and studies and how we are working to ensure that medicines and vaccines are made available for children in the right dose, formulation and at the right time.
Sign up to the Penta Newsletter to keep up to date with us!
Before proceeding, please read our Newsletter Privacy Notice.
Recent issues
April 2026: Why CMV deserves more attention
Did you know? Cytomegalovirus (CMV) is far more common than many people realise. While usually harmless in healthy adults, it can have serious consequences for infants and children, particularly those living with HIV. Congenital CMV affects around 0.67% of births worldwide, with rates up to three times higher in low-resource settings. It is a major cause of hearing loss and neurodevelopmental disability, yet awareness and routine screening remain limited.
March 2026: Join the fight against TB, HIV and AMR
This March, on International Women’s Day, our Young Reporter Arlene reflected on the crucial role that women have had in shaping the response to HIV/AIDS, and the need to continue amplifying women’s leadership in innovation. For World Tuberculosis (TB) Day, we turned our focus to the children who are too often left undiagnosed or diagnosed too late. Penta is advancing Point-of-Care tests and diagnostic tools for TB, aiming to make testing faster and more accessible, so every child has a fair chance at a healthy, TB-free future.
February 2026: Explore our research at CROI 2026
At this year’s Conference on Retroviruses and Opportunistic Infections (CROI), Penta once again had a strong presence, with oral presentations and posters highlighting progress from some of our studies. The D3 findings are especially significant for children and adolescents living with HIV. Results show that a two-drug regimen of dolutegravir/lamivudine (DTG/3TC) is just as effective as the standard three-drug approach, with many practical benefits that could improve daily life for children and their caregivers facing lifelong treatment.